Few moments in a hair loss treatment journey are more disorienting than the first one. A patient starts a medication intended to slow or reverse hair loss, and within a few weeks the pillow, the shower drain, and the bathroom sink seem to hold more hair than before. The instinct is reasonable: stop the treatment, because it appears to be making things worse. The biology, however, tells a different story. This early shedding phase is well documented in the dermatology literature, has a specific name (often called "dread shed" colloquially, or treatment-induced telogen effluvium clinically), and is generally considered a sign that the medication is engaging the hair cycle rather than failing.
This guide explains what is actually happening at the level of the follicle when shedding appears in the first weeks of treatment, why minoxidil and finasteride can both trigger it through different mechanisms, how long it typically lasts, and what kinds of shedding warrant a conversation with a clinician versus continued patience.
The hair growth cycle, in brief
Each follicle on the scalp moves through a repeating sequence of phases. Understanding the cycle is the prerequisite for understanding why a medication can cause a temporary increase in shedding.
Anagen: the active growth phase
Anagen is the phase during which the follicle is actively producing a hair shaft. On a healthy scalp, anagen lasts roughly 2 to 6 years per follicle, and at any given moment around 85 to 90 percent of scalp follicles are in anagen. The length of anagen is what determines how long a strand of hair can grow before it is shed.
In androgenetic alopecia, the duration of anagen progressively shortens with each cycle. The follicle still produces a hair, but for a shorter period, and the resulting strand is finer and shorter. Over many cycles, this process is described as follicle miniaturization, and it is the underlying mechanism behind most pattern hair loss.
Catagen and telogen: transition and rest
Catagen is a brief regression phase lasting roughly two to three weeks, during which the lower part of the follicle shrinks and growth halts. Telogen follows: a resting phase, typically lasting around three months, during which the old hair shaft is anchored in the follicle but no new growth is occurring. Roughly 10 to 15 percent of follicles are in telogen at any one time.
Exogen: the shedding phase
Exogen is the phase in which the resting hair is finally released and falls out, often as the new anagen hair starts to push up beneath it. Most people shed somewhere in the range of 50 to 100 hairs per day as a normal consequence of the exogen phase. This baseline shedding is unrelated to disease.
The relevant insight for treatment-induced shedding is this: a hair that enters telogen today will not typically be shed for weeks to months. Anything that shifts a large cohort of follicles into telogen at the same time, or that accelerates exit from telogen, will produce a coordinated shed several weeks later.
Why minoxidil triggers an early shed
Minoxidil is a vasodilator originally developed for blood pressure, repurposed topically and orally for androgenetic alopecia. Its mechanism in the follicle is still being characterized, but the consensus from clinical and laboratory studies is that minoxidil shortens the telogen phase and prolongs anagen, increasing the proportion of follicles actively producing hair.
For follicles already in telogen when treatment begins, the practical effect is that they are pushed out of the resting phase earlier than they otherwise would have been. To exit telogen and begin a new anagen cycle, the old resting hair has to be shed first. The result is a synchronized release of telogen hairs in the weeks following the start of treatment.
The standard description in the literature is that this shed begins around two to four weeks after starting minoxidil and resolves within about six to eight weeks. Trial data suggest most patients who shed early continue to respond favorably if they remain on treatment. For a deeper look at how this medication works at the follicle level, see how minoxidil treats hair loss.
It is worth noting that switching from topical to oral minoxidil, or increasing the dose, can reintroduce a shorter shedding episode as the cycle resynchronizes. The same is sometimes reported when patients move from twice-daily to once-daily dosing, or vice versa. Comparing the two formulations is covered in more depth in topical vs oral minoxidil.
Why finasteride can also trigger shedding
Finasteride works on a different axis: it inhibits type II 5-alpha reductase and reduces circulating and scalp DHT, the androgen primarily implicated in pattern hair loss. With less DHT acting on susceptible follicles, the miniaturization process slows or partially reverses, and miniaturized follicles can re-enter a fuller anagen phase.
When a previously miniaturized follicle is given the chance to produce a thicker, longer hair, it has to first shed the thin "vellus-like" strand it was producing under the influence of DHT. This is sometimes described as a "regrowth shed": the visible hair you see in the sink is the small, weak shaft being replaced by a stronger one underneath. The mechanism differs from minoxidil's, but the lived experience is similar: a transient rise in daily shedding within the first 8 to 16 weeks of starting treatment.
Trial protocols for finasteride generally instruct patients to expect that any improvement in hair count or scalp coverage will not be measurable until at least 3 to 6 months in, and that early shedding does not predict a worse long-term response. For a fuller account, see how finasteride treats hair loss.
Patients on combination therapy (topical minoxidil plus oral finasteride, for example) sometimes experience a more pronounced early shed than those on monotherapy, simply because two mechanisms are pushing the cycle simultaneously.
What the early shed typically looks like
Treatment-induced shedding has some recognizable features that distinguish it from worsening disease.
Timing
It usually begins 2 to 4 weeks after starting treatment, peaks somewhere around weeks 4 to 6, and tapers off by weeks 6 to 8. By the 12-week mark, daily shedding has generally returned to baseline or slightly below. There is individual variability, and some patients shed for closer to 12 weeks before stabilizing.
Volume
A patient who normally sheds 50 to 100 hairs daily may shed 150 to 300 during the peak of treatment-induced shedding. The hairs are typically full-length telogen hairs with a small white bulb at the root, indicating they completed their resting phase normally.
Pattern
The shed is generally diffuse, meaning hairs come out across the scalp rather than from a single patch. It is most noticeable on washing or brushing, when mechanical force releases the synchronized cohort of telogen hairs.
What it is not
Treatment-induced shedding does not typically present as patchy, circular bald spots (which can suggest alopecia areata). It does not typically come with redness, itching, scaling, or pain (which can suggest an inflammatory scalp condition). And it does not typically produce broken or fragmented hairs (which can suggest mechanical damage or a hair shaft disorder).
When shedding is expected versus when to seek evaluation
The general rule from dermatology guidelines is that an early, diffuse, time-limited shed in the first 8 weeks of treatment is expected and is not a reason to discontinue. Several patterns, however, warrant a conversation with a clinician.
- Shedding that is still escalating at 3 months on treatment, or that has not begun to taper by 4 months, may reflect an unrelated cause (thyroid disease, iron deficiency, postpartum changes, recent illness, or a new medication) rather than the treatment itself.
- Patchy hair loss with well-defined edges is not a typical pattern for treatment-induced shedding and should be evaluated.
- Scalp symptoms (burning, intense itch, persistent redness, scale, tenderness) in conjunction with shedding may indicate contact dermatitis to a topical formulation, seborrheic dermatitis, or another scalp disorder.
- Sudden, dramatic shedding (hundreds of hairs per day) months after starting treatment is more consistent with a separate telogen effluvium trigger than with the medication.
A clinician can help distinguish treatment-induced shedding from these alternatives, often with a simple history, scalp examination, pull test, and basic blood work where indicated.
Why staying on treatment through the shed matters
The most common reason patients fail to benefit from minoxidil or finasteride is not that the drug did not work biologically. It is that they discontinued during the early shedding phase before any meaningful regrowth could occur. Both medications require months of continuous use before the underlying changes in the hair cycle translate into a visible difference in count or density.
Stopping treatment during a shed has two consequences. First, the synchronized cohort of follicles that was about to enter a fuller anagen phase loses the pharmacologic support that would have driven that transition. Second, stopping treatment returns the scalp to its pre-treatment trajectory over the following 6 to 12 months, meaning any progress already made is gradually lost.
Realistic expectations for time on treatment are covered in detail in how long hair loss treatment takes, but the short version is that benefit is generally assessed at 6 and 12 months, not at 6 to 8 weeks. For an overview of the typical first six months on treatment, including the shed phase, see what to expect in the first 6 months.
Practical guidance during the shedding window
There is no medication or supplement that reliably shortens treatment-induced shedding. The cycle has to play out. A few practical points may help.
- Continue the prescribed medication as directed. Skipping doses to "let the scalp recover" tends to prolong the cycle resynchronization rather than shorten it.
- Avoid making other simultaneous changes (a new shampoo regimen, a new supplement, a new styling product) that might confound your assessment of what is causing the shed.
- Track the timeline with simple weekly photographs in consistent light, rather than trying to estimate shedding by counting hairs in the drain. Photographs are a much more reliable measure of trend over months.
- If the shed is genuinely worrying you, document it for your clinician (when it started, how long it has lasted, whether it is getting better or worse) rather than discontinuing treatment unilaterally.
For patients on finasteride or dutasteride who want to understand the difference between the two and how it relates to early shedding, see finasteride vs dutasteride. For patients deciding between minoxidil and finasteride or considering combination therapy, minoxidil vs finasteride lays out how the two mechanisms compare.
Considering medical assessment
Treatment-induced shedding is well described in the medical literature and is generally considered a transient feature of starting an effective therapy rather than a side effect to fear. That said, distinguishing it from other causes of shedding (nutritional, hormonal, inflammatory, or pattern-related) is best done with a clinician who can examine the scalp and review your history.
If you are early in treatment and shedding has you considering stopping, the most useful step is usually a brief check-in with the prescribing clinician to confirm that the pattern you are seeing fits the expected timeline. The decision to continue, adjust, or stop a medication should be made under physician supervision, with the full clinical picture in view, rather than in the moment after a stressful shower.
